RT Journal Article
SR Electronic
T1 Clinical performance of cell free DNA for fetal RhD detection in RhD-negative pregnant individuals from the US population
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.07.24.24310793
DO 10.1101/2024.07.24.24310793
A1 Nino, Julio F. Mateus
A1 Wynn, Julia
A1 Wiggins-Smith, Jenny
A1 Bryant, J. Brett
A1 Citty, Kris
A1 Citty, J. Kyle
A1 Ahuja, Samir
A1 Newman, Roger
YR 2024
UL http://medrxiv.org/content/early/2024/07/24/2024.07.24.24310793.abstract
AB Background Approximately 15% of pregnant women in the US are RhD-negative. To prevent alloimmunization, current national guidelines endorse the administration of prophylactic anti-D immune globulin (RhIG) at 28 weeks of gestation and in any other episodes where alloimmunization can occur, such as bleeding, pregnancy loss, trauma or invasive procedures. Alloimmunization only occurs if the fetus is RhD-positive; however, 40% of RhD-negative mothers carry an RhD-negative fetus, resulting in, under the current guidelines, the sometimes repeated, use of unnecessary RhIG.Objective We aimed to evaluate the performance of a next generation sequencing (NGS) with quantitative counting template (QCT) technology prenatal cell free DNA (cfDNA) assay in detecting the fetal RhD genotype in a diverse RhD-negative pregnant population in the United States (US).Study Design This retrospective study was conducted in four US healthcare centers. The same NGS QCT cfDNA fetal RhD assay was offered to non-alloimmunized, RhD-negative pregnant individuals. Rh immune globulin (RhIG) was administered at the discretion of the provider. The assay’s sensitivity, specificity, and accuracy were calculated considering the neonatal RhD serology results.Results A total of 401 non-alloimunized RhD-negative pregnancies were included in the analysis. Fetal RhD was detected in 261 cases (65%), whereas it was negative in 140 (35%). The D antigen cfDNA result was 100% concordant with the neonatal serology, resulting in 100% sensitivity and positive predictive value and (both 95% CI: 98.6%-100%) 100% specificity and negative predictive value (both 95% CI: 97.4%-100%). There were 10 pregnancies where the cfDNA analysis identified a non-RHD gene deletion, including RhDΨ (n=5) and RHD-CE-D hybrid variants (n=5). A total of 616 doses of RhIG were administered. Despite the fact that the study occurred prior to the current RhIG shortage and the recent American College (ACOG) advisory change, there was a marked decrease in the use of antenatal RhIG based on cfDNA results. This decrease was greater at certain sites and at later study periods. If the cfDNA results were fully utilized during the entire study period, up to 147 RhIG doses (24% of administered doses) could have been avoided, indicating the importance of guideline changes to support the use of cfDNA for fetal RhD detection to conserve this resource.Conclusion This cfDNA analysis via NGS for detecting fetal RhD status is highly accurate with no false positive or false negative results in 401 racial and ethnically diverse pregnancies. Our data support implementing this assay for the routine management of non-alloimmunized RhD-negative individuals. This approach will result in more efficient and targeted prenatal care with administration of RhIG only when medically indicated.AJOG at a GlanceWhy was this study conducted? To examine the performance of a next generation sequencing based quantitative cfDNA assay for detecting the fetal RhD genotype in RhD-negative pregnancies after 10 weeks of gestation.What are the key findings? In 401 cases analyzed, including 10 pregnancies with a non-RhD gene deletion, the fetal D antigen cfDNA result was 100% concordant with the neonatal serology, resulting in 100% (95% CI: 98.6%-100%) sensitivity and 100% (95% CI: 97.4%-100%) specificity. Informative results were obtained in 100% of the cases.What does this study add to what is already known? This RhD cfDNA assay is highly accurate for the diverse US population supporting its implementation in routine prenatal care of RhD-negative pregnant patients.Competing Interest StatementDr. Samir Ahuja is a paid consultant from BillionToOne, Inc. Julia Wynn is an employee of BillionToOne, Inc. and has options in the company Funding StatementParticipating clinical sites received research funding from the sponsor of the study, BillionToOne Inc.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All participating institutions and the sponsor site received approved by the WCG IRB (IRB#: 20234135). The study was exempted from patient consent as it was a retrospective study of medical records from clinical care.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesA complete set of anonymized data is available on request from the corresponding author.